Weekly Analysts’ Ratings Changes for Biomea Fusion (BMEA)

A number of firms have modified their ratings and price targets on shares of Biomea Fusion (NASDAQ: BMEA) recently:

• 10/14/2026 – Biomea Fusion had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $7.00 price target on the stock.
• 10/14/2026 – Biomea Fusion had its “buy” rating reaffirmed by HC Wainwright. They now have a $4.00 price target on the stock.
• 10/7/2026 – Biomea Fusion is now covered by Brookline Capital Markets. They set a “buy” rating on the stock.
• 10/5/2026 – Biomea Fusion was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/30/2026 – Biomea Fusion had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/28/2026 – Biomea Fusion had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 9/27/2026 – Biomea Fusion was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/19/2026 – Biomea Fusion was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/6/2026 – Biomea Fusion was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/29/2026 – Biomea Fusion was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/24/2026 – Biomea Fusion had its “buy” rating reaffirmed by HC Wainwright.

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.